Core Viewpoint - Aimeike, once a leading player in the medical beauty industry, is facing significant challenges with declining performance and ongoing disputes over product agency rights, prompting a recent board reshuffle to address these issues [2][3][20]. Company Overview - Aimeike's actual controller, Jian Jun, has been re-elected as chairman, with a stable core management team, while the new board secretary, Li Dongmei, is seen as a fresh face amid the company's current challenges [2]. - The company has experienced a dramatic decline in performance, with a first-time negative growth reported in the first half of 2025, and significant year-on-year drops in revenue and net profit [3][13]. Financial Performance - In the third quarter of 2025, Aimeike reported revenue of 566 million yuan and a net profit of 304 million yuan, representing declines of 21.27% and 34.61% year-on-year, respectively [3]. - As of November 21, 2025, Aimeike's stock price is 148 yuan per share, with a market capitalization of 44.8 billion yuan, down over 100 billion yuan from its peak [4]. - The company's financial struggles have also impacted Jian Jun's wealth, which has decreased significantly over the past two years [6]. Historical Growth Trajectory - Aimeike's growth trajectory has been closely tied to its innovative product development, with significant milestones including the launch of its first self-developed product in 2009 and the introduction of several key products that drove revenue growth [9][10]. - The company saw explosive growth from 2021 to 2023, with revenues increasing from 1.448 billion yuan in 2021 to 2.869 billion yuan in 2023, and net profits rising from 958 million yuan to 1.858 billion yuan during the same period [7][10]. Current Challenges - The company is now facing a decline in growth momentum, with projections for 2024 showing single-digit growth rates, and a significant drop in revenue and net profit in the first half of 2025 [13]. - The decline is attributed to the weakening performance of its core products, particularly the HiTi and Luhua Tianzi, which have seen substantial year-on-year revenue declines [13][14]. Market Competition - The competitive landscape in the medical beauty industry is intensifying, with new entrants and increased product offerings leading to a dilution of Aimeike's previous competitive advantages [14][19]. - The recent launch of competing products has further pressured Aimeike's market share, particularly in the neck wrinkle treatment segment [13][14]. Strategic Responses - In response to these challenges, Aimeike is focusing on diversifying its product offerings and enhancing its research and development capabilities, including the introduction of new products and expansion into biopharmaceuticals [15][17]. - The company has also pursued strategic acquisitions, such as the purchase of a majority stake in REGEN, to bolster its product portfolio and enhance its competitive position in the global market [17][18]. Agency Dispute - Aimeike is embroiled in a significant dispute over the agency rights for its AestheFill product, which has led to legal actions and could impact its market performance [18][20]. - The resolution of this dispute is critical for Aimeike's management team, as it seeks to stabilize the company amid declining market conditions and increasing competition [20].

21新健康 . 21世纪传媒 · 公众号矩阵成员。 以下文章来源于21新健康 ，作者韩利明 昔日有着"医美茅"之称的爱美客（300896.SZ），在业绩持续下滑、重大仲裁案悬而未决的关键节点，新一届董事会换届工作于日前 落下帷幕。 公司实际控制人、62岁的简军毫无悬念连任董事长及法定代表人，石毅峰、勾丽娜、尹永磊组成的核心管理层保持稳定。颇受市场 关注的是，董事会秘书简勇（简军之弟）正式辞任所有职务，李冬梅以"副总经理兼董事会秘书"的身份跻身管理层，成为此次换届 中的"新面孔"。 这位自2025年6月起担任爱美客董事会事务及法务总监的李冬梅被快速提拔，与公司当前核心困境形成微妙呼应。 换届前夕，爱美 客与江苏吴中围绕童颜针产品AestheFill（艾塑菲）的代理权争夺战已进入白热化阶段，甚至有投资者打趣"新董秘的首要任务或是 推动代理权争议妥善解决"。 市场的这份关切，本质上源于爱美客日益迫切的增长压力。作为2020年9月登陆A股的医美龙头，爱美客曾创下资本市场神话： 118.27元/股的发行价开盘即飙升至320元，2021年2月19日股价触及1331元历史高点， 总市值一度突破1500亿元，"女人的茅台"名 ...

"医美茅"爱美客跌落 昔日有着"医美茅"之称的爱美客(300896.SZ)，在业绩持续下滑、重大仲裁案悬而未决的关键节点，新一 届董事会换届工作于日前落下帷幕。 公司实际控制人、62岁的简军毫无悬念连任董事长及法定代表人，石毅峰、勾丽娜、尹永磊组成的核心 管理层保持稳定。颇受市场关注的是，董事会秘书简勇(简军之弟)正式辞任所有职务，李冬梅以"副总 经理兼董事会秘书"的身份跻身管理层，成为此次换届中的"新面孔"。 这位自2025年6月起担任爱美客董事会事务及法务总监的李冬梅被快速提拔，与公司当前核心困境形成 微妙呼应。换届前夕，爱美客与江苏吴中围绕童颜针产品AestheFill(艾塑菲)的代理权争夺战已进入白热 化阶段，甚至有投资者打趣"新董秘的首要任务或是推动代理权争议妥善解决"。 市场的这份关切，本质上源于爱美客日益迫切的增长压力。作为2020年9月登陆A股的医美龙头，爱美 客曾创下资本市场神话：118.27元/股的发行价开盘即飙升至320元，2021年2月19日股价触及1331元历史 高点，总市值一度突破1500亿元，"女人的茅台"名号响彻市场。 爱美客的成长轨迹，与简军的个人经历深度绑定。 公开资料显示 ...